Hospital
Emanate Health Foothill Presbyterian Hospital
Emanate Health Foothill Presbyterian Hospital was paid $9.78M by Medicaid between Jan 2018 and Dec 2024, across 210 billing codes. Its largest line is 0450, Emergency room services — 27% of everything it billed.
33Billing provider infoEMANATE HEALTH FOOTHILL PRESBYTERIAN HOSPITAL
GLENDORA, CA 91741
GLENDORA, CA 91741
33aNPI1992733513assigned 06/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.78M
24GClaims577,809
24DCodes billed210
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#183 of 410
Median peer was paid$6.90M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,099 | $1.04M | |
| 2019 | 78,467 | $1.22M | |
| 2020 | 65,544 | $1.12M | |
| 2021 | 71,730 | $1.40M | |
| 2022 | 82,776 | $1.62M | |
| 2023 | 107,802 | $1.83M | |
| 2024incomplete | 102,391 | $1.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 27% | 68,830 | 61,245 | $2.61M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.2% | 5,911 | 5,737 | $504K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 5,179 | 5,017 | $457K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.3% | 17,558 | 15,890 | $327K |
| 99199 | Unlisted special service, procedure or report | 3.0% | 8,473 | 7,391 | $297K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 1,870 | 1,834 | $296K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.8% | 8,775 | 7,663 | $277K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.8% | 16,391 | 15,082 | $276K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 6,596 | 6,191 | $259K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 1,344 | 1,251 | $246K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 3,235 | 2,943 | $238K |
| 80053 | Comprehensive metabolic panel | 2.3% | 30,637 | 28,159 | $225K |
198 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 3,783 | $185K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 34,539 | $168K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 15,885 | $167K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,863 | $143K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.4% | 2,719 | $136K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.2% | 7,486 | $117K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 3,001 | $111K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 2,907 | $107K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 5,499 | $102K |
| J3490 | Unclassified drugs | <1% | 20,593 | $94K |
| Z7502 | <1% | 2,288 | $86K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,952 | $80K |
| 0360 | <1% | 1,615 | $77K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,285 | $70K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,256 | $70K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 486 | $69K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 2,470 | $68K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,601 | $68K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,989 | $68K |
| 84484 | <1% | 10,412 | $68K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 671 | $67K |
| 99284 | Emergency room visit (serious) | <1% | 870 | $64K |
| 0250 | <1% | 17,431 | $56K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 910 | $52K |
| 83690 | <1% | 10,524 | $52K | |
| 93971 | <1% | 696 | $51K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 285 | $48K |
| 76830 | Ultrasound, transvaginal | <1% | 1,167 | $47K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,866 | $45K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,994 | $45K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,567 | $40K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,792 | $40K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,065 | $39K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,067 | $38K |
| 0270 | <1% | 14,775 | $38K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,350 | $37K |
| 82803 | <1% | 2,600 | $35K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,005 | $33K |
| 0301 | <1% | 629 | $33K | |
| 83880 | <1% | 1,837 | $32K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,900 | $31K |
| 81001 | <1% | 14,056 | $29K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 119 | $28K |
| 90715 | <1% | 1,000 | $27K | |
| 87040 | <1% | 2,878 | $27K | |
| 73630 | <1% | 1,571 | $27K | |
| 81025 | <1% | 6,585 | $26K | |
| 73610 | <1% | 1,445 | $26K | |
| 73564 | <1% | 1,101 | $21K | |
| 76801 | <1% | 515 | $20K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 595 | $20K |
| 81003 | <1% | 10,812 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,972 | $16K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,520 | $16K |
| 0637 | <1% | 5,342 | $15K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,227 | $15K |
| 88313 | <1% | 1,028 | $15K | |
| 84702 | <1% | 1,885 | $15K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 520 | $15K |
| A4649 | Surgical supply; miscellaneous | <1% | 2,990 | $14K |
| 73030 | <1% | 937 | $14K | |
| 73130 | <1% | 819 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,099 | $12K |
| 83735 | <1% | 2,653 | $12K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 957 | $12K |
| 87186 | <1% | 2,011 | $12K | |
| 85730 | <1% | 2,889 | $12K | |
| 83605 | <1% | 1,541 | $11K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,963 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,150 | $11K |
| 85610 | <1% | 3,823 | $11K | |
| 85379 | <1% | 1,441 | $10K | |
| 82550 | <1% | 2,476 | $10K | |
| 93970 | <1% | 90 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,327 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,111 | $9K |
| 99070 | <1% | 1,802 | $8K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 188 | $8K |
| 0710 | <1% | 873 | $8K | |
| 0762 | <1% | 93 | $8K | |
| 88312 | <1% | 1,047 | $8K | |
| 73110 | <1% | 536 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,235 | $7K |
| 73590 | <1% | 377 | $6K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,129 | $6K |
| 84439 | <1% | 2,356 | $6K | |
| 87276 | <1% | 1,273 | $6K | |
| 70486 | <1% | 72 | $6K | |
| 72131 | <1% | 77 | $6K | |
| 72100 | <1% | 351 | $6K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 139 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 277 | $6K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 55 | $6K |
| 80051 | <1% | 1,252 | $5K | |
| 99499 | <1% | 110 | $5K | |
| 86900 | <1% | 2,895 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,300 | $5K |
| 86850 | <1% | 1,523 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 996 | $4K |
| 87275 | <1% | 1,273 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,980 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,034 | $3K |
| 82962 | <1% | 1,648 | $3K | |
| 87430 | <1% | 506 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 838 | $3K |
| 0272 | <1% | 991 | $3K | |
| Z7610 | <1% | 254 | $3K | |
| 0420 | <1% | 112 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 514 | $3K |
| 94060 | <1% | 75 | $3K | |
| 87084 | <1% | 410 | $3K | |
| 73562 | <1% | 158 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 65 | $2K |
| 84703 | <1% | 867 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 206 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 422 | $2K |
| 73080 | <1% | 121 | $2K | |
| 94729 | <1% | 51 | $2K | |
| 71101 | <1% | 77 | $2K | |
| 73090 | <1% | 145 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 598 | $2K |
| 80061 | Lipid panel | <1% | 3,536 | $2K |
| 96376 | <1% | 655 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 286 | $2K |
| 85018 | <1% | 1,279 | $2K | |
| 87339 | <1% | 377 | $2K | |
| 97139 | <1% | 165 | $2K | |
| 73502 | <1% | 90 | $1K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 31 | $1K |
| 76870 | <1% | 40 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 108 | $1K |
| 86140 | <1% | 622 | $1K | |
| 71250 | <1% | 13 | $1K | |
| 0370 | <1% | 658 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,807 | $1K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 96 | $956.30 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 162 | $938.76 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,630 | $888.35 |
| 86901 | <1% | 455 | $874.44 | |
| 71010 | <1% | 52 | $774.28 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 189 | $735.01 |
| J1815 | Injection, insulin, per 5 units | <1% | 35 | $704.25 |
| 82553 | <1% | 97 | $696.71 | |
| 87420 | <1% | 173 | $649.45 | |
| 85652 | <1% | 686 | $556.76 | |
| A9270 | Non-covered item or service | <1% | 491 | $478.80 |
| 94727 | <1% | 12 | $353.42 | |
| 76857 | <1% | 12 | $301.14 | |
| 73060 | <1% | 14 | $225.76 | |
| 97750 | <1% | 12 | $224.17 | |
| 74018 | <1% | 26 | $215.34 | |
| 86592 | <1% | 442 | $205.18 | |
| 80074 | <1% | 54 | $199.86 | |
| 73620 | <1% | 12 | $197.98 | |
| 72040 | <1% | 12 | $195.57 | |
| 80076 | <1% | 56 | $159.44 | |
| 87806 | <1% | 44 | $147.04 | |
| 82607 | <1% | 614 | $146.80 | |
| 82728 | <1% | 293 | $138.13 | |
| 0160 | <1% | 13 | $122.28 | |
| 29125 | <1% | 29 | $116.67 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $116.37 |
| 82746 | <1% | 121 | $111.30 | |
| 87070 | <1% | 27 | $106.33 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 428 | $88.39 |
| 10060 | <1% | 13 | $85.25 | |
| 87807 | <1% | 13 | $76.62 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 53 | $74.89 |
| 88142 | <1% | 2,761 | $71.30 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 96 | $65.76 |
| 86703 | <1% | 100 | $61.97 | |
| 84550 | <1% | 160 | $60.47 | |
| 83540 | <1% | 177 | $55.21 | |
| 0324 | <1% | 47 | $30.96 | |
| 87210 | <1% | 12 | $24.17 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 239 | $22.33 |
| 82043 | <1% | 359 | $14.13 | |
| 83550 | <1% | 145 | $12.73 | |
| 84153 | <1% | 93 | $9.07 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 96 | $7.27 |
| 0636 | 0% | 170 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 356 | $0.00 |
| 0306 | 0% | 114 | $0.00 | |
| 0307 | 0% | 44 | $0.00 | |
| 84480 | 0% | 49 | $0.00 | |
| 87340 | 0% | 32 | $0.00 | |
| 0352 | 0% | 15 | $0.00 | |
| 0305 | 0% | 144 | $0.00 | |
| 86225 | 0% | 12 | $0.00 | |
| 76641 | 0% | 33 | $0.00 | |
| 0300 | 0% | 161 | $0.00 | |
| 0730 | 0% | 14 | $0.00 | |
| 0390 | 0% | 24 | $0.00 | |
| 86003 | 0% | 34 | $0.00 | |
| 0460 | 0% | 44 | $0.00 | |
| 0121 | 0% | 27 | $0.00 | |
| 82785 | 0% | 13 | $0.00 | |
| 86480 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHARMA, ROGER (EXECUTIVE VP/CFO)
Parent organizationEMANATE HEALTH
| Provider | Location | Paid |
|---|---|---|
| Emanate Health Medical Center | West Covina, CA | $23.44M |
| Emanate Health Medical Center | Covina, CA | $11.22M |
| Emanate Health Medical Center | Covina, CA | $163K |
| Emanate Health Foothill Presbyterian Hospital | Glendora, CA | $81K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.